Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ABC008 / Abcuro
NCT06450886: Long-term Extension Study of Ulviprubart (ABC008) in Subjects with Inclusion Body Myositis	Recruiting	2/3	270	US, RoW	Ulviprubart (ABC008)	Abcuro, Inc.	Inclusion Body Myositis (IBM)	01/29	04/29
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis	Active, not recruiting	2/3	231	Europe, Canada, US, RoW	ABC008	Abcuro, Inc., Syneos Health	Inclusion Body Myositis	11/25	12/25
NCT05532722: ABC008 in Subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)	Active, not recruiting	1/2	21	US	ABC008	Abcuro, Inc.	T-cell Large Granular Lymphocytic Leukemia	09/25	09/27
NCT04659031: A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)	Active, not recruiting	1	30	RoW	ABC008	Abcuro, Inc.	Inclusion Body Myositis	03/25	08/25